CStone制药公司报告,在治疗高级淋巴瘤方面CS5001的回复率很高。 CStone Pharmaceuticals reports high response rates for CS5001 in treating advanced lymphomas.

CStone制药公司在ASH年度会议上介绍了关于CS5001(反ROR1ADC)的令人鼓舞的数据。 CStone Pharmaceuticals presented encouraging data on CS5001, an anti-ROR1 ADC, at the ASH Annual Meeting. 该药物显示出以高客观响应率治疗高级淋巴瘤的前景:在建议的第二阶段,76.9%在高级B细胞淋巴瘤中,60.0%在Hodgkin淋巴瘤中,56.3%在非Hodgkin淋巴瘤中。 The drug shows promise in treating advanced lymphomas with high objective response rates: 76.9% at the recommended Phase 2 dose in advanced B-cell lymphoma, 60.0% in Hodgkin lymphomas, and 56.3% in non-Hodgkin lymphomas. 正在美国、澳大利亚和中国进行全球第一阶段的试验。 The global Phase 1 trials are ongoing in the U.S., Australia, and China.